HTG Licenses Merck's Breast Cancer Biomarker Patent Portfolio | GenomeWeb

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced it has licensed Merck's breast cancer biomarker patent portfolio.

The license allows HTG to develop, manufacture, and commercialize tests based on the portfolio, which is co-owned by the Netherlands Cancer Institute. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.